Thermo Fisher Scientific Inc. (0R0H.L)

ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1st International Societies of Investigative Dermatology meeting May 10-13 in Tokyo$20 million private placement led by BVF Partners with the potential to receive up to an additional $80 million if all warrants are exercised in full Company maintains healthy operating position with US$57.5 million in cash and cash eq